Market Research Logo

Uveal Melanoma - Pipeline Review, H2 2016

Uveal Melanoma - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Uveal Melanoma - Pipeline Review, H2 2016’, provides an overview of the Uveal Melanoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Uveal Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Uveal Melanoma
    • The report reviews pipeline therapeutics for Uveal Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Uveal Melanoma therapeutics and enlists all their major and minor projects
    • The report assesses Uveal Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Uveal Melanoma
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Uveal Melanoma
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Uveal Melanoma pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Uveal Melanoma Overview
    Therapeutics Development
    Pipeline Products for Uveal Melanoma - Overview
    Pipeline Products for Uveal Melanoma - Comparative Analysis
    Uveal Melanoma - Therapeutics under Development by Companies
    Uveal Melanoma - Therapeutics under Investigation by Universities/Institutes
    Uveal Melanoma - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Uveal Melanoma - Products under Development by Companies
    Uveal Melanoma - Products under Investigation by Universities/Institutes
    Uveal Melanoma - Companies Involved in Therapeutics Development
    Aura Biosciences, Inc.
    Bellicum Pharmaceuticals, Inc.
    Celldex Therapeutics, Inc.
    Cleveland BioLabs, Inc.
    Eli Lilly and Company
    Iconic Therapeutics, Inc.
    Immunocore Limited
    Navigen Pharmaceuticals, Inc.
    Novartis AG
    PEP-Therapy SAS
    Pfizer Inc.
    Spectrum Pharmaceuticals, Inc.
    Uveal Melanoma - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    alpelisib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AU-011 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BPX-701 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    crizotinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DPTC-9h - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    emibetuzumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    entolimod - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    glembatumumab vedotin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    hI-con1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HPH-196 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HPH-211 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IMCgp-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KCN-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LXS-196 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    merestinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NAV-2729 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nutlin-3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pasireotide ER - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sotrastaurin acetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sunitinib malate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine 2 for Melanoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    vincristine sulfate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Uveal Melanoma - Dormant Projects
    Uveal Melanoma - Discontinued Products
    Uveal Melanoma - Product Development Milestones
    Featured News & Press Releases
    Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016
    Mar 30, 2016: Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma
    Jan 25, 2016: Immunocore’s IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma
    Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC
    Sep 09, 2015: Immunocore’s IMCgp100 Accepted for Adaptive Pathway Pilot Programme
    Jun 29, 2015: Lilly and Immunocore To Conduct Phase Ib/II Clinical Trial Collaboration For Treatment Of uveal melanoma
    May 21, 2015: FDA Grants Orphan Drug Designation to Aura Biosciences’ Novel Treatment for Uveal Melanoma
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Uveal Melanoma, H2 2016
    Number of Products under Development for Uveal Melanoma - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Uveal Melanoma - Pipeline by Aura Biosciences, Inc., H2 2016
    Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016
    Uveal Melanoma - Pipeline by Celldex Therapeutics, Inc., H2 2016
    Uveal Melanoma - Pipeline by Cleveland BioLabs, Inc., H2 2016
    Uveal Melanoma - Pipeline by Eli Lilly and Company, H2 2016
    Uveal Melanoma - Pipeline by Iconic Therapeutics, Inc., H2 2016
    Uveal Melanoma - Pipeline by Immunocore Limited, H2 2016
    Uveal Melanoma - Pipeline by Navigen Pharmaceuticals, Inc., H2 2016
    Uveal Melanoma - Pipeline by Novartis AG, H2 2016
    Uveal Melanoma - Pipeline by PEP-Therapy SAS, H2 2016
    Uveal Melanoma - Pipeline by Pfizer Inc., H2 2016
    Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Uveal Melanoma - Dormant Projects, H2 2016
    Uveal Melanoma - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Uveal Melanoma, H2 2016
    Number of Products under Development for Uveal Melanoma - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report